Aptalis Pharma Inactive 10-Q2011 Q2 Quarterly report

Filed: 13 May 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Bad

New words: Aeroquin, aerosol, Aquisition, bps, broad, capture, composition, cystic, deep, digit, discretion, divestiture, enable, engine, extinguishment, floor, footprint, highest, indemnity, innovative, installment, involuntary, legacy, length, levofloxacin, Lone, lump, meaningfully, mentioned, merger, Mpex, mutually, organizational, permanent, pilot, Pinnacle, platform, prepaid, prime, prototype, provisional, pulmonary, purport, reassessing, repaid, repatriation, Restucturing, robust, segment, skilled, Spinco, Star, stemming, strive, succeeding, sum, surviving, Unextended, unfunded, unmet, view, workforce

Removed: ACTIGALL, adverse, adversely, agreed, ahead, ANDA, announcement, anticipated, assessment, bond, capacity, carried, carry, challenged, claim, contracting, corporate, decision, deducted, delay, depend, derive, designed, determination, digestive, dollar, dosage, earlier, entry, euro, evaluate, exclusion, exclusivity, expanded, extent, fact, factor, focused, formulary, FORTE, franchise, GI, greater, guarantee, guarantor, identification, identifying, impaired, implement, improved, inflation, instituted, intellectual, judicial, key, largest, launched, licensed, lifecycle, longer, lower, manufacture, mesalamine, move, multinational, obsolete, obtaining, occurring, offer, operate, opposed, outsource, packaging, paragraph, pari, passu, paying, PEP, positive, potential, potentially, power, prepayment, presently, prevailing, prevent, production, protected, put, rank, rapidly, recent, rectal, referred, regulation, replacement, represented, repurchase, retire, satisfy, schedule, scheduled, scope, seek, specific, stable, substitute, suffering, SULCRATE, suspension, sustained, tract, transition, trial, unbranded, updated, wholesaler

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Aptalis Pharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Aptalis Pharma Inc. (the “Company”) for the period ending March 31, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Senior Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:

	1)		The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2)		The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

Date: May 13, 2011


/s/ Steve Gannon
Steve Gannon
Senior Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer)

Page 1